Global life sciences and diagnostics company Danaher Corporation (NYSE:DHR) on Thursday announced a research collaboration with Stanford University to develop smart microscopes for cancer drug screening.

The collaboration aims to use spatial biology and artificial intelligence to analyse tumour microenvironments and predict drug responses. The goal is to reduce cancer drug development failure rates caused by tumour heterogeneity.

Involving Leica Microsystems and Stanford researcher Emma Lundberg, the project is part of Danaher's Beacons programme, which funds product-driven scientific research.